Connect public, paid and private patent data with Google Patents Public Datasets

A novel process for amorphous rosuvastatin calcium

Info

Publication number
WO2005021511A1
WO2005021511A1 PCT/IN2003/000288 IN0300288W WO2005021511A1 WO 2005021511 A1 WO2005021511 A1 WO 2005021511A1 IN 0300288 W IN0300288 W IN 0300288W WO 2005021511 A1 WO2005021511 A1 WO 2005021511A1
Authority
WO
Grant status
Application
Patent type
Prior art keywords
rosuvastatin
calcium
amorphous
process
solvent
Prior art date
Application number
PCT/IN2003/000288
Other languages
French (fr)
Inventor
Reddy Bandi Parthasaradhi
Reddy Kura Rathnakar
Reddy Rapolu Raji
Reddy Dasari Muralidhara
Original Assignee
Hetero Drugs Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom

Abstract

The present invention provides a novel process for the preparation of amorphous rosuvastatin calcium.

Description

A NOVEL PROCESS FOR AMORPHOUS ROSUVASTATIN CALCIUM

FILELD OF THE INVENTION

The present invention provides a novel process for the preparation of amorphous rosuvastatin calcium. BACKGROUND OF THE INVENTION

Rosuvastatin of formula (1 ):

or (+)-7-[4-(4-f!uorophenyl)-6-isopropyl-2-(N-methyl-N-methyl sulfonyl amino)pyrimidin-5-yl]-(3R,5S)-dihydroxy-(E)-6-heptenoic acid and its salts are 3- hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase inhibitors and useful in the treatment of hypercholesterolemia, hyperlipoproteinemia and atherosclerosis. The therapeutic uses of rosuvastatin calcium and its related compounds were disclosed in US 5,260,440. Process for the preparation of amorphous(powder) rosuvastatin calcium was described in US 5,260,440. WO 00/42024 disclosed a crystalline form (form A) of rosuvastatin calcium. Various crystalline salts of rosuvastatin were disclosed in WO 01/60804. We have discovered a simple novel process for the preparation of sufficiently stable amorphous rosuvastatin calcium. The amorphous form produced by the novel process has better dissolution characteristics than the crystalline form known in the art. The object of the present invention is to provide a novel process for the preparation of amorphous rosuvastatin calcium and a pharmaceutical composition containing it.

DETAILED DESCRIPTION OF THE INVENTION In accordance with the present invention, there is provided a novel process for the preparation of amorphous rosuvastatin calcium. The amorphous rosuvastatin calcium is characterized by having broad x-ray diffraction spectrum as in figure 1. In accordance with the present invention, a process is provided for preparation of amorphous rosuvastatin calcium. Amorphous rosuvastatin calcium is prepared by dissolving rosuvastatin calcium in an alcohol, a ketone or an ester solvent and removing the solvent. The alcohol solvent is selected from the group consisting of methanol, ethanol, isopropyl alcohol, tert-butyl alcohol and n-butyl alcohol. The ketone solvent is selected from the group consisting of acetone, diethyl ketone, methylethyl ketone, methylisobutyl ketone and methylpropyl ketone. The ester solvent is selected from ethylacetate and methylacetate. A mixture of two or more of these solvents may also be used. The preferable alcohols are ethanol and methanol. The solvent may be removed from the solution by vacuum drying, freeze- drying, lyophilization or spray drying. Rosuvastatin calcium obtained by a known process may be used in the process. In accordance with the present invention, there is provided a pharmaceutical composition comprising amorphous rosuvastatin calcium and a pharmaceutically acceptable carrier or diluent.

BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is ' a x-ray powder diffraction spectrum of amorphous rosuvastatin calcium. x-Ray powder diffraction spectrum was measured on a Bruker axs D8 advance x-ray powder diffractometer having a copper-Kr radiation.

The invention will now be further described by the following non-limiting examples. Example 1 Rosuvastatin calcium (25 gm) is dissolved in ethanol (250 ml). The solution is subjected to vacuum drying at about 55°C for 10 hours to give 23 gm of amorphous rosuvastatin calcium. Example 2 Rosuvastatin calcium (25 gm) is dissolved in methanol (200 ml). The solution is subjected to spray drying at about 50°C for 8 hours to give 22.5 gm of amorphous rosuvastatin calcium. Example 3 Rosuvastatin calcium (20 gm) is dissolved in water (200 ml). The solution is subjected to lyophilization to give 18 gm of amorphous rosuvastatin calcium.

Claims

We claim:
1. A process for preparation of amorphous rosuvastatin calcium, which comprises the steps of: a) dissolving rosuvastatin calcium in a solvent; and b) removing the solvent from the solution formed in step (a) by vacuum drying, freeze drying, lyophilization or spray drying; wherein the solvent is selcted from methanol, ethanol, isopropyl alcohol, tert- butyl alcohol, n-butyl alcohol, acetone, diethyl ketone, methylethyl ketone, methylisobutyl ketone, methylpropyl ketone, ethylacetate, methylacetate and a mixture thereof.
2. A process according to claim 1 , wherein the solvent is ethanol.
3. A process according to claim 1 , wherein the solvent is methanol.
4. A process according to claim 1, wherein the solvent is removed by vacuum drying.
5. A process according to claim 1, wherein the solvent is removed by spray drying.
6. A pharmaceutical composition comprising amorphous rosuvastatin calcium and a pharmaceutically acceptable carrier or diluent.
PCT/IN2003/000288 2003-08-27 2003-08-27 A novel process for amorphous rosuvastatin calcium WO2005021511A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/IN2003/000288 WO2005021511A1 (en) 2003-08-27 2003-08-27 A novel process for amorphous rosuvastatin calcium

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IN2003/000288 WO2005021511A1 (en) 2003-08-27 2003-08-27 A novel process for amorphous rosuvastatin calcium

Publications (1)

Publication Number Publication Date
WO2005021511A1 true true WO2005021511A1 (en) 2005-03-10

Family

ID=34259913

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2003/000288 WO2005021511A1 (en) 2003-08-27 2003-08-27 A novel process for amorphous rosuvastatin calcium

Country Status (1)

Country Link
WO (1) WO2005021511A1 (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005077917A1 (en) * 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Amorphous salts of rosuvastatin
US7244844B2 (en) 2003-12-02 2007-07-17 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
US7396927B2 (en) 2003-08-28 2008-07-08 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
US7612203B2 (en) 2005-02-22 2009-11-03 Teva Pharmaceutical Industries Ltd. Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
JP2010503723A (en) * 2006-09-18 2010-02-04 リチュテル・ゲデオン・ヴェジェーセティ・ジャール・ニュイルヴァーノシャン・ミューコェデー・レースヴェーニュタールシャシャーグRichter Gedeon Nyrt. Rosuvastatin calcium containing pharmaceutical compositions
US7777034B2 (en) 2003-11-24 2010-08-17 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
US7868169B2 (en) 2005-08-16 2011-01-11 Teva Pharmaceutical Industries, Ltd. Crystalline rosuvastatin intermediate
US7994178B2 (en) 2006-09-18 2011-08-09 Teva Pharmaceutical Industries, Ltd. Crystalline rosuvastatin calcium and compositions thereof for treatment of hyperlipidaemia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260440A (en) * 1991-07-01 1993-11-09 Shionogi Seiyaku Kabushiki Kaisha Pyrimidine derivatives
WO2001060804A1 (en) * 2000-02-15 2001-08-23 Astrazeneca Ab Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
WO2003097614A2 (en) * 2002-05-21 2003-11-27 Ranbaxy Laboratories Limited Process for the preparation of rosuvastatin

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260440A (en) * 1991-07-01 1993-11-09 Shionogi Seiyaku Kabushiki Kaisha Pyrimidine derivatives
WO2001060804A1 (en) * 2000-02-15 2001-08-23 Astrazeneca Ab Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
WO2003097614A2 (en) * 2002-05-21 2003-11-27 Ranbaxy Laboratories Limited Process for the preparation of rosuvastatin

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7396927B2 (en) 2003-08-28 2008-07-08 Teva Pharmaceutical Industries Ltd. Process for preparation of rosuvastatin calcium
US7777034B2 (en) 2003-11-24 2010-08-17 Teva Pharmaceutical Industries Ltd. Crystalline ammonium salts of rosuvastatin
US7692008B2 (en) 2003-12-02 2010-04-06 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
US7244844B2 (en) 2003-12-02 2007-07-17 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
US7741482B2 (en) 2003-12-02 2010-06-22 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
US7692009B2 (en) 2003-12-02 2010-04-06 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
US7692010B2 (en) 2003-12-02 2010-04-06 Teva Pharmaceutical Industries Ltd. Reference standard for characterization of rosuvastatin
US8487097B2 (en) 2003-12-02 2013-07-16 Teva Pharmacedutical Industries Ltd. Reference standard for characterization of rosuvastatin
WO2005077917A1 (en) * 2004-01-19 2005-08-25 Ranbaxy Laboratories Limited Amorphous salts of rosuvastatin
US7612203B2 (en) 2005-02-22 2009-11-03 Teva Pharmaceutical Industries Ltd. Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
US8063211B2 (en) 2005-02-22 2011-11-22 Teva Pharmaceutical Industries, Ltd. Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
US7868169B2 (en) 2005-08-16 2011-01-11 Teva Pharmaceutical Industries, Ltd. Crystalline rosuvastatin intermediate
JP2010503723A (en) * 2006-09-18 2010-02-04 リチュテル・ゲデオン・ヴェジェーセティ・ジャール・ニュイルヴァーノシャン・ミューコェデー・レースヴェーニュタールシャシャーグRichter Gedeon Nyrt. Rosuvastatin calcium containing pharmaceutical compositions
US7994178B2 (en) 2006-09-18 2011-08-09 Teva Pharmaceutical Industries, Ltd. Crystalline rosuvastatin calcium and compositions thereof for treatment of hyperlipidaemia

Similar Documents

Publication Publication Date Title
US20050209259A1 (en) Novel anhydrous amorphous forms of rosuvastatin calcium, pitavastatin calcium and fluvastatin sodium
US20050080134A1 (en) Process for preparation of rosuvastatin calcium
WO1994016693A1 (en) Stable oral ci-981 formulation and process of preparing same
WO2002059087A1 (en) Preparation of non-crystalline atorvastatin calcium
WO2004108691A1 (en) Improved production of rosuvastatin calcium salt
WO2005054207A1 (en) Process for the preparation of pyrimidine derivatives
WO2006136408A2 (en) Process for preparing pure amorphous rosuvastatin calcium
US7511140B2 (en) Process for preparing the calcium salt of rosuvastatin
WO2001060804A1 (en) Crystalline salts of 7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-(3r,5s)-3,5-dihydroxyhept-6-enoic acid
WO2005023779A1 (en) Crystalline form of bis [(e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6 -enoicacid] calcium salt
US20040010151A1 (en) Lansoprazole polymorphs and processes for preparation thereof
US20040242899A1 (en) Crystalline forms VI and VII of atrovastatin calcium
WO2000042024A1 (en) Crystalline bis[(e)-7- [ 4-(4- fluorophenyl)- 6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin -5-yl] (3r,5s)-3, 5-dihydroxyhept -6-enoic acid]calcium salt
WO2007000121A1 (en) A method for the production of the hemi-calcium salt of (e)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3r,5s)-3,5-dihydroxyhept-6-enoic acid
US20070099994A1 (en) Rosuvastatin calcium with a low salt content
US20080045711A1 (en) Crystalline forms of pemetrexed diacid and processes for the preparation thereof
US20050143396A1 (en) Novel crystalline forms of ziprasidone hydrochloride
WO2007096588A1 (en) Salt of cd 80 antagonist
WO2009118598A1 (en) Process for the manufacture of rosuvastatin calcium with high purity
WO2008038132A1 (en) Crystalline diamine salts of rosuvastatin
Patil et al. Generation of 1: 1 carbamazepine: nicotinamide cocrystals by spray drying
US20060258882A1 (en) Rosuvastatin and salts thereof free of rosuvastatin alkylether and a process for the preparation thereof
US20120083517A1 (en) Polymorphs of saxagliptin hydrochloride and processes for preparing them
US7300938B2 (en) Polymorphs of imatinib mesylate
CN1543468A (en) Processes for preparing calcium salt forms of statins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct app. not ent. europ. phase
NENP Non-entry into the national phase in:

Ref country code: JP